Man Group
NPCE icon

Man Group’s Neuropace NPCE Stock Holding History

Man Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
84,073
+40,176
+92% +$647K ﹤0.01% 1757
2026
Q1 		$577K Buy
43,897
+22,271
+103% +$334K ﹤0.01% 2032
2025
Q4 		$334K Buy
21,626
+1,920
+10% +$25.7K ﹤0.01% 1995
2025
Q3 		$203K Buy
+19,706
New +$186K ﹤0.01% 2103
2024
Q3 		– Sell
-38,470
Closed -$291K – 2125
2024
Q2 		$291K Buy
38,470
+528
+1% +$5.33K ﹤0.01% 1791
2024
Q1 		$501K Buy
37,942
+18,644
+97% +$266K ﹤0.01% 1777
2023
Q4 		$199K Buy
+19,298
New +$154K ﹤0.01% 1920

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Man Group's NPCE Position: Q2 2026 in Review

Man Group increased its Neuropace (NPCE) stake by 92% in Q2 2026, buying an estimated $647K and bringing the position to 84,073 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1757.

Man Group first reported a position in NPCE in Q4 2023 and has held it in 7 quarters since. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Man Group held 84,073 shares of Neuropace worth $1.34M as of Q2 2026.
  • Man Group bought 40,176 Neuropace shares in Q2 2026, an estimated $647K.
  • Neuropace made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1757 holding.
  • Man Group first reported a position in Neuropace in Q4 2023 and has held it in 7 quarters since.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.